Predicate |
Object |
assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_f58e027d80c9f42687e27e11d4a8cc6a |
classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-622 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2319-03 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2319-02 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-00 |
classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K39-001112 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K35-17 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-2803 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K14-70521 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K14-7051 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-00 |
classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K35-17 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N5-0783 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K14-705 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K16-28 |
filingDate |
2020-10-07-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_c13348f9129cffbccad85bdb1c1adf85 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_09d47eddb7c2b77980817e2c772f61d2 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_e3811b4649dab525afedad9156c4eead http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_ee7ed5e13872b0f14c6cb64f793ce612 |
publicationDate |
2021-04-15-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
publicationNumber |
WO-2021071962-A1 |
titleOfInvention |
Enhanced chimeric antigen receptor for immune effector cell engineering and use thereof |
abstract |
Provided are methods and compositions for obtaining functionally enhanced derivative effector cells obtained from the differentiation of genomically engineered iPSCs. The derivative cells provided herein have stable and functional genome editing that delivers improved or enhanced therapeutic effects. Also provided are therapeutic compositions and the use thereof comprising the functionally enhanced derivative effector cells alone, or with antibodies or checkpoint inhibitors in combination therapies. |
isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-11459372-B2 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2023129937-A1 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-11591381-B2 |
priorityDate |
2019-10-07-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
type |
http://data.epo.org/linked-data/def/patent/Publication |